Immunoassay Validation: Analytical Controls and FDA Guidance

Immunoassay validation is the documented process of demonstrating that an analytical method performs reliably for its intended use, with accuracy, precision, specificity, and sensitivity established under defined conditions. For laboratory students, technicians, researchers, and diagnostic professionals, validation provides the evidence that results generated by an immunoassay are trustworthy for clinical or regulatory decisions. This article presents a practical framework for validating immunoassays, covering key analytical parameters, the role of quality control materials, and expectations aligned with FDA guidance documents. The framework applies to ligand binding assays including ELISA, rapid tests, and automated immunoassay platforms used in diagnostic and research settings.

At a Glance: Immunoassay Validation Parameters and Control Decisions

The table below summarizes the core validation parameters, the analytical controls that support each parameter, and the acceptance considerations that guide decision-making during validation studies.

Regulatory Context for Immunoassay Validation

Regulatory expectations for immunoassay validation have evolved through multiple guidance documents and industry consensus activities. The FDA Bioanalytical Method Validation Guidance provides the foundational framework for validating methods used to measure therapeutic candidates and their metabolites in support of pharmacokinetic evaluations. This guidance addresses the key elements required for demonstrating that a bioanalytical method is reliable and reproducible for its intended use. The FDA guidance applies to both small molecules and macromolecules, though ligand binding assays used for macromolecular therapeutics present unique validation considerations due to their nonlinear response characteristics and matrix effects.

The scientific community has engaged in ongoing discussions about how to interpret and apply FDA guidance to macromolecular therapeutics. The Third American Association of Pharmaceutical Scientists and FDA Bioanalytical Workshop held in 2006 addressed bioanalytical assays used for quantifying therapeutic candidates in support of pharmacokinetic evaluations. One goal of that workshop was to discuss best practices in bioanalysis regardless of the size of the therapeutic candidates. Because of the nature of ligand binding assays, attempts have been made within the scientific community to use statistical approaches to interpret acceptance criteria aligned with prestudy validation and in-study sample analysis processes. Topics discussed included using the total error criterion or confidence interval approaches for assay acceptance and using anchor calibrators to fit nonlinear regression models.

For vaccine immunoassays specifically, the lack of clarity in regulatory guidance has driven efforts to harmonize validation approaches. The urgency and importance of organizing a global effort to harmonize clinical assay validation specific to the vaccine industry was identified during the drafting of the 2020 White Paper in Bioanalysis due to the lack of clarity and regulatory guidance in vaccine immunoassay validation. The Workshop on Recent Issues in Bioanalysis issues the White Paper in Bioanalysis yearly, which provides detailed discussions and recommendations on vaccine assay validation. Since 2017, participation in the working groups by vaccine assay validation experts and regulators has increased due to the format where industry leaders and regulators can exchange ideas on topics of interest. In early 2021, vaccine manufacturers approached the workshop organizers to support the authorship and publication of an overarching vaccine assay validation document based on discussions and consensus starting with immunogenicity assays. A vaccine immunogenicity assay validation working group was assembled consisting of 16 companies, with work on the first white paper starting in April 2021 focusing on vaccine ligand binding assay validation.

The regulatory landscape continues to adapt for point-of-care diagnostics. Regulatory frameworks are evolving in parallel with technological advances, with the FDA's lifecycle oversight of AI-enabled devices, the European In Vitro Diagnostic Regulation's expanded evidence requirements, and the WHO Prequalification program all emphasizing continuous post-market surveillance. Rigorous validation, including analytical accuracy, clinical performance in intended-use settings, and usability testing, remains central to ensuring reliability in decentralized environments.

Core Principles of Immunoassay Validation

Validation of an immunoassay begins with a clear definition of the intended use. The intended use determines which validation parameters are critical and what acceptance criteria are appropriate. An assay intended for qualitative screening may require different validation emphasis than an assay intended for quantitative measurement of a therapeutic protein in patient samples.

The World Health Organization Laboratory Quality Management System Handbook provides guidance on the quality system elements that support reliable laboratory testing. The handbook addresses the management of quality across the total testing process, from pre-analytical through post-analytical phases. For immunoassay validation, the quality system framework supports documentation, training, equipment maintenance, and record keeping that are essential for demonstrating method reliability.

The National Center for Advancing Translational Sciences Assay Guidance Manual provides detailed recommendations for assay development and validation in translational research settings. The manual addresses the practical aspects of developing robust assays, including reagent selection, assay optimization, and validation study design. For researchers developing immunoassays, the manual serves as a reference for the technical parameters that must be evaluated during validation.

Accuracy and Recovery

Accuracy in immunoassay validation refers to the closeness of agreement between the measured value and the true concentration of the analyte in the sample. Accuracy is typically assessed through recovery studies, where known amounts of analyte are spiked into the sample matrix and the measured concentration is compared to the expected value. Recovery within defined limits across the measuring range demonstrates that the assay can accurately quantify the analyte in the intended matrix.

For the anthrax lethal toxin neutralization assay, validation demonstrated that accuracy was maintained even in samples with minimal neutralizing capacity, and linearity was noted when sample dilutions resulted in accurate prediction of the maximum and minimum response values. This example illustrates that accuracy assessment must include samples across the full measuring range, including low concentrations near the detection limit.

Precision and Reproducibility

Precision describes the degree of scatter among individual measurements of the same sample. Precision is evaluated at multiple levels, including within-run precision, between-run precision, between-day precision, and between-operator precision. The coefficient of variation is the standard metric for expressing precision, with lower values indicating better reproducibility.

The anthrax lethal toxin neutralization assay validation showed a high level of repeatability and reproducibility, particularly for a bioassay. Inter-assay variability in absorbance values was the most prominent negative finding, but an acceptable level was demonstrated using a ratio of the test serum effective dose to the reference standard effective dose. Cell passage number and cell plating density were identified as critical parameters responsible for inter-assay variability in absorbance values. This finding highlights the importance of controlling all assay variables during validation and routine use.

For the fully automated glial fibrillary acidic protein immunoassay, precision yielded coefficients of variation below 10 percent across all concentration ranges. This level of precision is typical for well-validated automated immunoassay platforms and demonstrates the importance of automation in reducing manual variability.

Specificity and Interference

Specificity is the ability of the assay to measure the target analyte without interference from other substances present in the sample matrix. Specificity is assessed through cross-reactivity testing with structurally related compounds, interference testing with medications and endogenous substances, and evaluation of matrix effects.

The ReEBOV Antigen Rapid Test validation provides an example of comprehensive specificity assessment. The rapid test demonstrated sensitivity to three species of Ebolavirus associated with human disease, with no cross-reactivity by pathogens associated with non-EBOV febrile illness, including malaria parasites. Interference testing exhibited no reactivity by medications in common use. This approach to specificity testing ensures that the assay produces accurate results in the clinical populations where it will be used.

For the glial fibrillary acidic protein immunoassay, interference testing showed less than 7 percent deviation for cross-reactants, common medications, and disease-specific therapeutics. This level of interference testing provides confidence that the assay results are not confounded by substances commonly present in patient samples.

Sensitivity and Detection Limits

Sensitivity in immunoassay validation encompasses the limit of blank, limit of detection, and lower limit of quantification. The limit of blank is the highest apparent analyte concentration expected when replicates of a blank sample containing no analyte are measured. The limit of detection is the lowest analyte concentration that can be reliably distinguished from the limit of blank. The lower limit of quantification is the lowest concentration at which the analyte can be quantified with acceptable accuracy and precision.

The ReEBOV Antigen Rapid Test validation established limits of detection of 4.7 nanograms per test in serum and 9.4 nanograms per test in whole blood. Quantitative reverse transcription-polymerase chain reaction testing of nonhuman primate samples determined the range to be equivalent to 3.0 times 10 to the fifth power to 9.0 times 10 to the eighth power genomes per milliliter. This example demonstrates how detection limits are established and how they relate to clinically relevant analyte concentrations.

The glial fibrillary acidic protein immunoassay achieved a lower limit of quantification of 0.083 picograms per milliliter with an analytical measurement range of 0.083 to 640 picograms per milliliter. Linearity demonstrated less than 9 percent deviation across the measurement range. These performance characteristics illustrate the sensitivity that can be achieved with modern immunoassay platforms.

For the galactose-deficient IgA1 time-resolved fluorescence immunoassay, the detection limit was 0.20 response units per milliliter with a quantification range of 0.20 to 600 response units per milliliter. The assay demonstrated acceptable analytical performance with intra-assay coefficients of variation from 2.32 to 5.49 percent and inter-assay coefficients of variation from 3.97 to 5.23 percent, with recoveries from 89.80 to 103.76 percent.

Analytical Controls in Immunoassay Validation

Analytical controls are materials of known composition that are used to monitor the performance of an immunoassay. Controls serve different purposes depending on where they are used in the assay workflow. Calibrators establish the relationship between the measured signal and the analyte concentration. Quality control materials verify that the assay is performing within established acceptance criteria during routine use. Reference standards provide the basis for assigning values to calibrators and controls.

Calibrators and Standard Curves

Calibrators are materials with known concentrations of the analyte that are used to generate the standard curve. The standard curve describes the relationship between the measured signal and the analyte concentration across the measuring range. For ligand binding assays, the standard curve is typically nonlinear and requires appropriate curve fitting to accurately describe the relationship.

The use of anchor calibrators has been discussed as an approach to fit nonlinear regression models in ligand binding assays. Anchor calibrators are points outside the analytical measuring range that help stabilize the curve fit at the extremes of the range. This approach can improve the accuracy of concentration estimates for samples near the upper and lower limits of quantification.

Quality Control Materials

Quality control materials are analyzed alongside patient samples to monitor assay performance during routine use. Controls should be prepared in the same matrix as the test samples and should span the measuring range, including concentrations near the lower limit of quantification, mid-range concentrations, and concentrations near the upper limit of quantification.

The development of lyophilized plasma-based quality control materials for hepatitis C virus antibody testing represents an approach to creating stable, matrix-appropriate controls for infectious disease serology. Lyophilization provides stability during storage and transport, allowing laboratories to use consistent control materials across testing sites and over time.

Commercially available immunoassay controls, such as those offered by Randox and other manufacturers, provide ready-to-use materials for monitoring assay performance. These controls are typically manufactured from human or animal matrices with analytes added at defined concentrations. When selecting commercial controls, laboratories should verify that the control matrix is appropriate for the assay and that the analyte concentrations span the clinically relevant range.

Reference Standards

Reference standards are highly characterized materials that serve as the basis for assigning values to calibrators and controls. Reference standards may be international standards established by organizations such as the World Health Organization, or they may be in-house reference materials characterized by the laboratory or manufacturer.

For the anthrax lethal toxin neutralization assay, the reference standard played a critical role in maintaining accuracy across runs. The neutralization ratio of the test serum effective dose to the reference standard effective dose was used to demonstrate acceptable inter-assay variability. This approach normalizes results to the reference standard, reducing the impact of day-to-day assay variability.

Practical Validation Workflow

The validation workflow proceeds through defined stages, from pre-validation planning through validation execution and documentation. Each stage requires specific decisions about study design, acceptance criteria, and documentation.

Step 1: Define Intended Use and Validation Scope

The first step in validation is to define the intended use of the assay. The intended use statement should specify the analyte, the sample matrix, the clinical or research context, and the decision that will be made based on the results. The intended use determines which validation parameters are required and what acceptance criteria are appropriate.

For an assay intended to support pharmacokinetic evaluations of a therapeutic protein, the validation must address accuracy, precision, specificity, sensitivity, and stability in the relevant matrix. For a qualitative screening assay, the validation may focus more heavily on specificity and the cut-off that distinguishes positive from negative results.

Step 2: Select Analytical Controls and Reference Materials

The selection of analytical controls and reference materials should occur during the planning phase. The laboratory should identify the source of calibrators, quality control materials, and reference standards. The matrix of the controls should match the matrix of the test samples as closely as possible.

For cross-species testing, additional feasibility experiments may be required. The anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay was validated for human serum samples, but additional testing was warranted for direct immunobridging comparability between humans and nonhuman primates. Method feasibility experiments were performed to assess cross-species reactivity and parallelism between human and nonhuman primate serum samples. The secondary antibody conjugate was found to be favorably cross-reactive with nonhuman primate samples, and the serum samples diluted in parallel when tested side-by-side in the enzyme-linked immunosorbent assay. A subsequent matrix qualification and partial validation were performed to characterize assay performance for nonhuman primate test samples.

Step 3: Conduct Pre-Validation Experiments

Pre-validation experiments, sometimes called feasibility or optimization studies, are conducted to establish the assay conditions that will be used in the formal validation. These experiments address reagent concentrations, incubation times, wash conditions, and other assay parameters. The goal is to establish a robust assay protocol before beginning formal validation studies.

The National Center for Advancing Translational Sciences Assay Guidance Manual provides recommendations for assay optimization that support the development of robust, reproducible assays. Optimization experiments should address the factors that are most likely to affect assay performance, including antibody concentrations, blocking conditions, and detection reagent concentrations.

Step 4: Execute Validation Studies

Formal validation studies are conducted according to a pre-defined validation protocol. The protocol specifies the number of runs, the number of replicates, the concentration levels tested, and the acceptance criteria for each parameter. Validation studies should be conducted by trained personnel using the final assay protocol.

For the anthrax lethal toxin neutralization assay, validation was performed in accordance with the FDA Bioanalytical Method Validation Guidance for Industry and the FDA Good Laboratory Practice for Nonclinical Laboratory Studies. The validation addressed repeatability, reproducibility, accuracy, linearity, specificity, and robustness. Robustness studies identified cell passage number and cell plating density as critical parameters that may be responsible for inter-assay variability in absorbance values.

Step 5: Analyze Validation Data and Establish Acceptance Criteria

Validation data are analyzed to determine whether the assay meets the pre-defined acceptance criteria. Statistical analysis should address the variability of the assay across runs, days, and operators. The results of the validation studies inform the establishment of acceptance criteria for routine assay use.

For the glial fibrillary acidic protein immunoassay, all analytical criteria were met. Precision yielded coefficients of variation below 10 percent across all concentration ranges. Sensitivity parameters included a lower limit of quantification of 0.083 picograms per milliliter and an analytical measurement range of 0.083 to 640 picograms per milliliter. Linearity demonstrated less than 9 percent deviation across the measurement range. Plasma samples remained stable over 48 hours at room temperature with less than 4 percent deviation and five freeze-thaw cycles with less than 9 percent deviation.

Step 6: Document Validation Results

Validation documentation should provide a complete record of the validation studies, including the protocol, raw data, statistical analysis, and conclusions. The documentation should be sufficient to allow an independent reviewer to understand what was done and to evaluate whether the validation meets regulatory expectations.

The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of documentation as a component of the quality system. Documentation provides evidence that the laboratory has demonstrated the reliability of its methods and supports the traceability of results.

Method Comparison and Cross-Validation

Method comparison studies are conducted when a new assay is introduced to replace an existing method, when results from different methods will be compared, or when an assay is transferred between laboratories. Method comparison provides evidence that the new method produces results that are consistent with the established method.

A study comparing a microfluidic immunoassay to two liquid chromatography-tandem mass spectrometry methods for the quantitative analysis of monoclonal antibodies in human plasma provides an example of method comparison. All three methods were validated or cross-validated according to the 2018 FDA guidance and were then compared by quantitating eighteen patient samples on each platform. The concentrations obtained from each method were compared using percent variability, as well as Bland-Altman and Pearson correlation plots, to determine agreeability and linear correlation between methods. All three methods aligned well with each other, though the mass spectrometry methods achieved significantly improved sensitivity with a lower limit of quantification of 0.300 nanograms per milliliter compared to 6.00 nanograms per milliliter for the ligand binding assay.

For the glial fibrillary acidic protein immunoassay, method comparison against an established assay demonstrated strong correlation with a correlation coefficient of 0.945 but systematic proportional bias, yielding 3 percent of the comparator assay values. This finding illustrates that method comparison studies may reveal systematic differences between methods that must be considered when interpreting results.

Records and Measurements for Validation

Records are the foundation of validation evidence. The laboratory should maintain complete records of all validation activities, including the validation protocol, raw data, calculations, and final reports. Records should be sufficiently detailed to allow reconstruction of the validation studies and to support the conclusions drawn from the data.

Essential Validation Records

The following records should be maintained for each immunoassay validation:

• Validation protocol with defined acceptance criteria
• Reagent lot numbers and expiration dates
• Equipment calibration and maintenance records
• Raw data from all validation experiments
• Statistical analysis outputs
• Final validation report with conclusions and any deviations from the protocol
• Training records for personnel who performed the validation studies

Measurements to Document

The measurements documented during validation should include:

• Signal responses for all calibrators, controls, and test samples
• Calculated concentrations for all samples
• Recovery values for accuracy assessment
• Coefficient of variation values for precision assessment
• Cross-reactivity values for specificity assessment
• Limit of blank, limit of detection, and lower limit of quantification values
• Stability data for samples and reagents

Common Failure Patterns in Immunoassay Validation

Understanding common failure patterns helps laboratories anticipate problems and design validation studies that will identify issues before the assay is used for patient testing.

Matrix Effects

Matrix effects occur when components of the sample matrix interfere with the assay, producing inaccurate results. Matrix effects are particularly common in ligand binding assays because the sample matrix can affect antibody binding, enzyme activity, or detection signal. The World Health Organization Laboratory Quality Management System Handbook addresses the importance of using matrix-appropriate controls and calibrators to minimize matrix effects.

Hook Effect

The hook effect, also known as the high-dose hook effect, occurs when very high concentrations of analyte saturate the binding sites of the capture and detection antibodies, producing a falsely low signal. The hook effect can cause samples with very high analyte concentrations to be reported as low or negative. Validation studies should include testing of high-concentration samples to identify whether the hook effect occurs and to establish the concentration range where results are reliable.

Cross-Reactivity

Cross-reactivity occurs when antibodies in the assay bind to substances other than the target analyte. Cross-reactivity can produce false positive results or inaccurate quantification. The ReEBOV Antigen Rapid Test validation demonstrated the importance of cross-reactivity testing by showing no cross-reactivity with pathogens associated with non-EBOV febrile illness, including malaria parasites.

Reagent Instability

Reagent instability can cause assay performance to change over time, producing inaccurate results. Stability studies should address reagent storage conditions, reconstitution stability, and on-board stability for automated platforms. The anthrax lethal toxin neutralization assay validation demonstrated that the assay remained stable against time, temperature, and freeze-thaw effects on the reference standards, but not on the toxin. This finding highlights the importance of stability testing for each reagent component.

Operator Variability

Operator variability occurs when different operators perform the assay differently, producing different results. The anthrax lethal toxin neutralization assay validation identified cell passage number and cell plating density as critical parameters that may be responsible for inter-assay variability. Standardized protocols and operator training can reduce operator variability.

Limitations of Immunoassay Validation

Validation demonstrates that an assay performs reliably under defined conditions, but validation has inherent limitations that laboratories must recognize.

Validation Does Not Guarantee Performance in All Populations

Validation studies are conducted with a defined set of samples and matrices. The performance of the assay in populations or matrices not included in the validation studies cannot be assumed. For example, the anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay was initially validated for human serum samples, and additional testing was required to demonstrate suitability for nonhuman primate samples.

Validation Is Specific to the Validated Conditions

Validation results apply to the specific assay protocol, reagents, equipment, and conditions that were validated. Changes to any of these elements may require revalidation or at least verification that the change does not affect assay performance.

Statistical Limitations

Validation studies use a limited number of runs and samples to estimate assay performance. The estimates of accuracy, precision, and other parameters have associated uncertainty. Laboratories should consider the statistical power of their validation studies when interpreting the results.

Biosafety Considerations in Immunoassay Validation

Biosafety is an important consideration when validating immunoassays, particularly when the assay involves infectious agents or biological samples that may contain pathogens. The World Health Organization Laboratory Biosafety Manual provides guidance on the safe handling of biological materials in laboratory settings.

Validation studies involving infectious agents require appropriate containment measures based on the risk group of the agent. The ReEBOV Antigen Rapid Test validation involved Ebola virus, a Biosafety Level 4 pathogen, and required appropriate containment for handling infectious materials. Laboratories should conduct a risk assessment before beginning validation studies and implement appropriate biosafety measures.

For assays involving human samples, standard precautions should be followed to prevent exposure to bloodborne pathogens. The Laboratory Biosafety Manual provides guidance on the use of personal protective equipment, safe handling of sharps, and decontamination procedures.

Professional Escalation Criteria

Laboratories should have defined criteria for escalating validation issues to appropriate personnel. Escalation is appropriate when validation results do not meet acceptance criteria, when unexpected problems occur during validation, or when the validation reveals issues that may affect patient safety.

Escalation Criteria for Validation Failures

The following situations warrant escalation to laboratory management or the quality assurance function:

• Validation results that do not meet pre-defined acceptance criteria
• Repeated failures in precision or accuracy studies
• Unexpected cross-reactivity or interference findings
• Evidence of reagent instability or lot-to-lot variability
• Discrepancies between the new method and an established comparison method
• Any finding that suggests the assay may produce clinically misleading results

Escalation Criteria for Safety Concerns

The following situations warrant escalation to the biosafety officer or institutional safety committee:

• Any exposure to infectious materials during validation studies
• Evidence of contamination of reagents or equipment
• Failure of containment equipment
• Any incident that may compromise the safety of laboratory personnel

Frequently Asked Questions

What is the difference between validation and verification of an immunoassay?

Validation is the process of demonstrating that an assay performs reliably for its intended use, including establishing accuracy, precision, specificity, sensitivity, and other performance parameters. Verification is the process of confirming that an assay performs as expected in the laboratory where it will be used, typically for assays that have already been validated by the manufacturer. Verification is less extensive than validation and focuses on confirming that the laboratory can reproduce the manufacturer's claimed performance.

How many runs are needed for immunoassay validation?

The number of runs needed depends on the assay type and the validation parameters being assessed. Precision studies typically require multiple runs across multiple days to capture between-run and between-day variability. The FDA Bioanalytical Method Validation Guidance provides expectations for the number of runs and replicates needed to support validation. Laboratories should design validation studies with sufficient runs to provide reliable estimates of assay performance.

What is the role of quality control materials in immunoassay validation?

Quality control materials are used to monitor assay performance during routine use. During validation, quality control materials are used to assess precision and to establish the acceptance criteria that will be used for routine quality control. Quality control materials should be matrix-appropriate and should span the measuring range of the assay.

How do I establish acceptance criteria for a new immunoassay?

Acceptance criteria should be established based on the intended use of the assay and the performance that is achievable with the assay technology. Acceptance criteria should be defined in the validation protocol before validation studies begin. The FDA Bioanalytical Method Validation Guidance and the National Center for Advancing Translational Sciences Assay Guidance Manual provide recommendations for acceptance criteria for various validation parameters.

What is the hook effect and how do I test for it during validation?

The hook effect occurs when very high concentrations of analyte saturate the binding sites of the capture and detection antibodies, producing a falsely low signal. To test for the hook effect during validation, include samples with very high analyte concentrations and verify that the measured concentrations are accurate. If the hook effect is present, the assay should include a dilution protocol or the measuring range should be adjusted to avoid reporting falsely low results for high-concentration samples.

When is method comparison required during immunoassay validation?

Method comparison is required when a new assay will replace an established method, when results from different methods will be compared for clinical decisions, or when an assay is transferred between laboratories. Method comparison studies provide evidence that the new method produces results consistent with the established method. The FDA Bioanalytical Method Validation Guidance addresses the expectations for method comparison and cross-validation studies.

What documentation is needed for immunoassay validation?

Documentation for immunoassay validation should include the validation protocol, raw data from all experiments, statistical analysis outputs, and a final validation report. The documentation should be sufficient to allow an independent reviewer to understand what was done and to evaluate whether the validation meets regulatory expectations. The World Health Organization Laboratory Quality Management System Handbook provides guidance on documentation requirements within the laboratory quality system.

How do I handle validation failures?

Validation failures should be investigated to identify the root cause. The investigation should address the assay protocol, reagents, equipment, operator performance, and environmental conditions. If the root cause is identified and corrected, the affected validation studies should be repeated. If the root cause cannot be identified or the assay cannot be brought into acceptable performance, the validation should be terminated and the assay should not be used for patient testing.

Related Diagnostic Guides

• Process Controls in PCR: Internal Amplification Controls and Their Role in Validation
• Multiplex Real-Time RT-PCR for Simultaneous Detection of Porcine Epidemic Diarrhea Virus, Transmissible Gastroenteritis Virus, and Porcine Deltacoronavirus in Oral Fluids: Analytical Sensitivity, Specificity, and Field Validation
• Multiplex Real-Time RT-PCR for Simultaneous Detection of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Porcine Circovirus Type 2 (PCV2), and Swine Influenza A Virus (SIV) in Oral Fluids: Analytical Sensitivity, Specificity, and Field Validation
• Multiplex Real-Time RT-PCR Panels for Simultaneous Detection of Canine Respiratory Pathogens: Optimization, Analytical Sensitivity, and Clinical Validation
• Digital Droplet PCR (ddPCR) for Absolute Quantification of Swine Enteric Coronaviruses in Fecal and Oral Fluid Samples: Analytical Sensitivity and Clinical Utility

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Harmonization of Vaccine Ligand Binding Assays Validation.. Bioanalysis, 2024.
• Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.. Journal of immunological methods, 2004.
• Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.. The Journal of infectious diseases, 2016.
• Key elements of bioanalytical method validation for macromolecules.. The AAPS journal, 2007.
• Advances in Point-of-Care Infectious Disease Diagnostics: Integration of Technologies, Validation, Artificial Intelligence, and Regulatory Oversight.. Diagnostics (Basel, Switzerland), 2025.
• Comparison of methods for quantitative analysis of ranibizumab and bevacizumab in human plasma using various bioanalytical techniques, including microfluidic immunoassay, triple quadrupole, and high-resolution liquid chromatography-tandem mass spectrometry approaches.. Journal of pharmaceutical and biomedical analysis, 2022.
• Validation of the anthrax lethal toxin neutralization assay.. Biologicals : journal of the International Association of Biological Standardization, 2004.
• Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples.. PloS one, 2020.
• Analytical Performance and Evaluation in Clinical Cohorts of a Fully Automated Immunoassay for Plasma Glial Fibrillary Acidic Protein.. 2026.
• Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.. 2026.
• A multivariable probability score integrating routine immunoassay results for the immunological assessment of antisynthetase syndrome.. 2026.
• Development and Characterization of Dual-Platform Lyophilized Plasma-Based Quality Control Materials for Hepatitis C Virus Antibody Testing. 2026.
• Report on the AAPS Immunogenicity Guidance Forum. AAPS Journal, 2019.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.